Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KRAS G12D (on/off) inhibitor, in patients with KRAS G12D-mutant solid tumors.
The preliminary safety and tolerability data indicate that VS-7375 can be administered at efficacious doses to manage gastrointestinal side effects. Following encouraging preliminary data, the company has initiated patient enrollment for the first dose-escalation combination cohort.
“While still early, we are pleased to see anti-tumor activity among pre-treated patients with advanced pancreatic cancer and other solid tumors. As we continue monotherapy dose escalation, we are excited to open the combination cohort evaluating VS-7375 with cetuximab just months after trial initiation,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
Subject to the outcome of the Phase 1 dose escalation, Verastem intends to initiate a combination expansion cohort in colorectal cancer. It also plans to select the recommended Phase 2 dose and advance subsequent efficacy and safety analysis in patients with advanced pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).
Verastem, Inc. is a biopharmaceutical company that develops and commercializes new medicines for patients with cancers driven by the RAS/MAPK signaling pathway. It develops novel small-molecule drugs, including inhibitors targeting RAF/MEK, FAK, and KRAS G12D.
READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.
This article is originally published at Insider Monkey.
Hedge Fund Resource Center